Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > How does Accelerated Approval work

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Sep 10, 2024 9:56pm

249 Views

Post# 36217847

RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work

Hello Note and you wrote...;

Comment by Noteableon Sep 10, 2024 4:44pm

RE:RE:RE:RE:RE:RE:How does Accelerated Approval work

3 registration studies that are already in progress - 1 in mBC (Bracelet-1) and 2 in mPDAC (Goblet-1).

I do not see anywhere that shows we have 3 registration studies underway. We do not have any trial protocols or any fda approvals yet.
If you mean that the company is hoping to plan for 3 registration trials then that is different.

<< Previous

Bullboard Posts

Next >>

The deep connection between mining and First Nations in Canada